Maaike Alblas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maaike Alblas has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Ewout W. Steyerberg
Department of Public Health Erasmus MC–University Medical Center Rotterdam Rotterdam The Netherlands
2 shared publicationsAdam B. Schweber
Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, New York, USA
1 shared publicationAnn G. Zauber
Department of Epidemiology & Biostatistics Memorial Sloan Kettering Cancer Center New York NY USA
1 shared publication- Benjamin Hendrik Salampessij
Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
1 shared publication Christian Brooks
Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, New York, USA
1 shared publication- Djuna L. Cahen
Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 October 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6835-6844
Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study
Background To evaluate the cost-effectiveness of prophylactic hysterectomy (PH) in women with Lynch syndrome (LS). Methods We developed a microsimulation model incorporating the natural history for the development of hyperplasia with and without atypia into endometrial cancer (EC) based on the MISCAN-framework. We simulated women identified as first-degree relatives (FDR) with LS of colorectal cancer patients after universal testing for LS. We estimated costs and benefits of offering this cohort PH, accounting for reduced quality of life after PH and for having EC. Three minimum ages (30/35/40) and three maximum ages (70/75/80) were compared to no PH. Results In the absence of PH, the estimated number of EC cases was 300 per 1,000 women with LS. Total associated costs for treatment of EC were $5.9 million. Offering PH to FDRs aged 40-80 years was considered optimal. This strategy reduced the number of endometrial cancer cases to 5.4 (-98%), resulting in 516 quality-adjusted life years (QALY) gained and increasing the costs (treatment of endometrial cancer and PH) to $15.0 million (+154%) per 1,000 women. PH from earlier ages was more costly and resulted in fewer QALYs, although this finding was sensitive to disutility for PH. Conclusions Offering PH to 40- to 80-year-old women with LS is expected to add 0.5 QALY per person at acceptable costs. Women may decide to have PH at a younger age, depending on their individual disutility for PH and premature menopause.
- 1 October 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6835-6844
Open AccessCost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study
Background To evaluate the cost-effectiveness of prophylactic hysterectomy (PH) in women with Lynch syndrome (LS). Methods We developed a microsimulation model incorporating the natural history for the development of hyperplasia with and without atypia into endometrial cancer (EC) based on the MISCAN-framework. We simulated women identified as first-degree relatives (FDR) with LS of colorectal cancer patients after universal testing for LS. We estimated costs and benefits of offering this cohort PH, accounting for reduced quality of life after PH and for having EC. Three minimum ages (30/35/40) and three maximum ages (70/75/80) were compared to no PH. Results In the absence of PH, the estimated number of EC cases was 300 per 1,000 women with LS. Total associated costs for treatment of EC were $5.9 million. Offering PH to FDRs aged 40-80 years was considered optimal. This strategy reduced the number of endometrial cancer cases to 5.4 (-98%), resulting in 516 quality-adjusted life years (QALY) gained and increasing the costs (treatment of endometrial cancer and PH) to $15.0 million (+154%) per 1,000 women. PH from earlier ages was more costly and resulted in fewer QALYs, although this finding was sensitive to disutility for PH. Conclusions Offering PH to 40- to 80-year-old women with LS is expected to add 0.5 QALY per person at acceptable costs. Women may decide to have PH at a younger age, depending on their individual disutility for PH and premature menopause.
- Open Access
- 19 December 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (3) , 495-502
Predicting keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of a multivariable risk‐prediction model
Background Patients with actinic keratosis (AK) are at increased risk for developing keratinocyte carcinoma (KC) but predictive factors and their risk rates are unknown. Objectives To develop and internally validate a prediction model to calculate the absolute risk of a first KC in AK patients. Methods The risk prediction model was based on the prospective population‐based Rotterdam Study cohort. We hereto analyzed data of participants with at least 1 AK‐lesion at cohort baseline using a multivariable Cox proportional hazards model and included 13 a priori defined candidate predictor variables considering phenotypic, genetic and lifestyle risk factors. KCs were identified by linkage of the data with the Dutch Pathology Registry. Results Of the 1,169 AK‐participants at baseline, 176 (15.1%) developed a KC after a median follow‐up of 1.8 years. The final model with significant predictors was obtained after backward stepwise selection and comprised the presence of 4‐9 AKs (hazard ratio (HR): 1.68, 95% confidence interval (CI): 1.16‐2.42), 10 or more AKs (HR: 2.43, 95% CI: 1.64‐3.61), AK‐localization on upper extremities (HR: 0.75, 95% CI: 0.52‐1.08) or elsewhere except the head (HR: 1.40, 95% CI: 0.98‐2.01), and coffee consumption (HR: 0.92, 95% CI: 0.84‐1.01). Evaluation of the discriminative ability of the model showed a bootstrap validated c‐index of 0.60. Conclusions We showed that the risk of KC in patients with AK can be calculated with the use of four easily assessable predictor variables. Given the c‐index, extension of the model with additional, currently unknown predictor variables is desirable.
- 19 December 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (3) , 495-502
Open AccessPredicting keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of a multivariable risk‐prediction model
Background Patients with actinic keratosis (AK) are at increased risk for developing keratinocyte carcinoma (KC) but predictive factors and their risk rates are unknown. Objectives To develop and internally validate a prediction model to calculate the absolute risk of a first KC in AK patients. Methods The risk prediction model was based on the prospective population‐based Rotterdam Study cohort. We hereto analyzed data of participants with at least 1 AK‐lesion at cohort baseline using a multivariable Cox proportional hazards model and included 13 a priori defined candidate predictor variables considering phenotypic, genetic and lifestyle risk factors. KCs were identified by linkage of the data with the Dutch Pathology Registry. Results Of the 1,169 AK‐participants at baseline, 176 (15.1%) developed a KC after a median follow‐up of 1.8 years. The final model with significant predictors was obtained after backward stepwise selection and comprised the presence of 4‐9 AKs (hazard ratio (HR): 1.68, 95% confidence interval (CI): 1.16‐2.42), 10 or more AKs (HR: 2.43, 95% CI: 1.64‐3.61), AK‐localization on upper extremities (HR: 0.75, 95% CI: 0.52‐1.08) or elsewhere except the head (HR: 1.40, 95% CI: 0.98‐2.01), and coffee consumption (HR: 0.92, 95% CI: 0.84‐1.01). Evaluation of the discriminative ability of the model showed a bootstrap validated c‐index of 0.60. Conclusions We showed that the risk of KC in patients with AK can be calculated with the use of four easily assessable predictor variables. Given the c‐index, extension of the model with additional, currently unknown predictor variables is desirable.
- Open Access
- 19 August 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 50 (7) , 789-799
Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression
Summary: Background: Because most pancreatic intraductal papillary mucinous neoplasms (IPMNs) will never become malignant, currently advocated long‐term surveillance is low‐yield for most individuals.Aim: To develop a score chart identifying IPMNs at lowest risk of developing worrisome features or high‐risk stigmata.Methods: We combined prospectively maintained pancreatic cyst surveillance databases of three academic institutions. Patients were included if they had a presumed side‐branch IPMN, without worrisome features or high‐risk stigmata at baseline (as defined by the 2012 international Fukuoka guidelines), and were followed ≥ 12 months. The endpoint was development of one or more worrisome features or high‐risk stigmata during follow‐up. We created a multivariable prediction model using Cox‐proportional logistic regression analysis and performed an internal‐external validation.Results: 875 patients were included. After a mean follow‐up of 50 months (range 12‐157), 116 (13%) patients developed worrisome features or high‐risk stigmata. The final model included cyst size (HR 1.12, 95% CI 1.09‐1.15), cyst multifocality (HR 1.49, 95% CI 1.01‐2.18), ever having smoked (HR 1.40, 95% CI 0.95‐2.04), history of acute pancreatitis (HR 2.07, 95% CI 1.21‐3.55), and history of extrapancreatic malignancy (HR 1.34, 95% CI 0.91‐1.97). After validation, the model had good discriminative ability (C‐statistic 0.72 in the Mayo cohort, 0.71 in the Columbia cohort, 0.64 in the Erasmus cohort).Conclusion: In presumed side branch IPMNs without worrisome features or high‐risk stigmata at baseline, the Dutch‐American Risk stratification Tool (DART‐1) successfully identifies pancreatic lesions at low risk of developing worrisome features or high‐risk stigmata.
- 19 August 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 50 (7) , 789-799
Open AccessDevelopment of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression
Summary: Background: Because most pancreatic intraductal papillary mucinous neoplasms (IPMNs) will never become malignant, currently advocated long‐term surveillance is low‐yield for most individuals.Aim: To develop a score chart identifying IPMNs at lowest risk of developing worrisome features or high‐risk stigmata.Methods: We combined prospectively maintained pancreatic cyst surveillance databases of three academic institutions. Patients were included if they had a presumed side‐branch IPMN, without worrisome features or high‐risk stigmata at baseline (as defined by the 2012 international Fukuoka guidelines), and were followed ≥ 12 months. The endpoint was development of one or more worrisome features or high‐risk stigmata during follow‐up. We created a multivariable prediction model using Cox‐proportional logistic regression analysis and performed an internal‐external validation.Results: 875 patients were included. After a mean follow‐up of 50 months (range 12‐157), 116 (13%) patients developed worrisome features or high‐risk stigmata. The final model included cyst size (HR 1.12, 95% CI 1.09‐1.15), cyst multifocality (HR 1.49, 95% CI 1.01‐2.18), ever having smoked (HR 1.40, 95% CI 0.95‐2.04), history of acute pancreatitis (HR 2.07, 95% CI 1.21‐3.55), and history of extrapancreatic malignancy (HR 1.34, 95% CI 0.91‐1.97). After validation, the model had good discriminative ability (C‐statistic 0.72 in the Mayo cohort, 0.71 in the Columbia cohort, 0.64 in the Erasmus cohort).Conclusion: In presumed side branch IPMNs without worrisome features or high‐risk stigmata at baseline, the Dutch‐American Risk stratification Tool (DART‐1) successfully identifies pancreatic lesions at low risk of developing worrisome features or high‐risk stigmata.
- Open Access
- 18 February 2019
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 9 (1) , 14
Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?
Information of an individual’s epigenome can be useful in cancer screening to enable personalised decision making on participation, treatment options and further screening strategies. However, adding this information might result in complex risk predictions on multiple diseases, unsolicited findings and information on (past) environmental exposure and behaviour. This complicates informed consent procedures and may impede autonomous decision-making. In this article we investigate and identify the specific features of epigenetic risk-stratified cancer screening that challenge the current informed consent doctrine. Subsequently we describe current and new informed consent models and the principle of respect for autonomy and argue for a specific informed consent model for epigenetic risk-stratified screening programmes. Next, we propose a framework that guides the development of Patient Decision Aids (PDAs) to support informed consent and promote autonomous choices in the specific context of epigenetic cancer screening programmes.
- 18 February 2019
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 9 (1) , 14
Open AccessAutonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?
Information of an individual’s epigenome can be useful in cancer screening to enable personalised decision making on participation, treatment options and further screening strategies. However, adding this information might result in complex risk predictions on multiple diseases, unsolicited findings and information on (past) environmental exposure and behaviour. This complicates informed consent procedures and may impede autonomous decision-making. In this article we investigate and identify the specific features of epigenetic risk-stratified cancer screening that challenge the current informed consent doctrine. Subsequently we describe current and new informed consent models and the principle of respect for autonomy and argue for a specific informed consent model for epigenetic risk-stratified screening programmes. Next, we propose a framework that guides the development of Patient Decision Aids (PDAs) to support informed consent and promote autonomous choices in the specific context of epigenetic cancer screening programmes.
- Open Access
- 20 October 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 797
The effect of cost-sharing design characteristics on use of health care recommended by the treating physician; a discrete choice experiment
Cost-sharing programs are often too complex to be easily understood by the average insured individual. Consequently, it is often difficult to determine the amount of expenses in advance. This may preclude well-informed decisions of insured individuals to adhere to medical treatment advised by the treating physician. Preliminary research has showed that the uncertainty in these cost-sharing payments are affected by four design characteristics, i.e. 1) type of payments (copayments, coinsurances or deductibles), 2) rate of payments, 3) annual caps on cost-sharing and 4) moment that these payments must be made (directly at point of care or billed afterwards by the insurer). An online discrete choice experiment was used to assess the extent to which design characteristics of cost-sharing programs affect the decision of individuals to adhere to recommended care (prescribed medications, ordered diagnostic tests and referrals to medical specialist care). Analyses were performed using mixed multinomial logits. The questionnaire was completed by 7921 members of a patient organization. Analyses showed that 1) cost-sharing programs that offer clear information in advance on actual expenses that are billed afterwards, stimulate adherence to care recommended by the treating physician; 2) the relative importance of the design characteristics differed between respondents who reported to have forgone health care due to cost-sharing and those who did not; 3) price-awareness among respondents was limited; 4) the utility derived from attributes and respondents’ characteristics were positively correlated; 5) an optimized cost-sharing program revealed an adherence of more than 72.9% among those who reported to have forgone health care. The analyses revealed that less complex cost-sharing programs stimulate adherence to recommended care. If these programs are redesigned accordingly, individuals who had reported to have forgone a health service recommended by their treating physician due to cost-sharing, would be more likely to use this service. Such redesigned programs provide a policy option to reduce adverse health effects of cost-sharing in these groups. Considering the upcoming shift from volume-based to value-based health care provision, insights into the characteristics of a cost-sharing program that stimulates the use of recommended care may help to design value-based insurance plans.
- 20 October 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 797
Open AccessThe effect of cost-sharing design characteristics on use of health care recommended by the treating physician; a discrete choice experiment
Cost-sharing programs are often too complex to be easily understood by the average insured individual. Consequently, it is often difficult to determine the amount of expenses in advance. This may preclude well-informed decisions of insured individuals to adhere to medical treatment advised by the treating physician. Preliminary research has showed that the uncertainty in these cost-sharing payments are affected by four design characteristics, i.e. 1) type of payments (copayments, coinsurances or deductibles), 2) rate of payments, 3) annual caps on cost-sharing and 4) moment that these payments must be made (directly at point of care or billed afterwards by the insurer). An online discrete choice experiment was used to assess the extent to which design characteristics of cost-sharing programs affect the decision of individuals to adhere to recommended care (prescribed medications, ordered diagnostic tests and referrals to medical specialist care). Analyses were performed using mixed multinomial logits. The questionnaire was completed by 7921 members of a patient organization. Analyses showed that 1) cost-sharing programs that offer clear information in advance on actual expenses that are billed afterwards, stimulate adherence to care recommended by the treating physician; 2) the relative importance of the design characteristics differed between respondents who reported to have forgone health care due to cost-sharing and those who did not; 3) price-awareness among respondents was limited; 4) the utility derived from attributes and respondents’ characteristics were positively correlated; 5) an optimized cost-sharing program revealed an adherence of more than 72.9% among those who reported to have forgone health care. The analyses revealed that less complex cost-sharing programs stimulate adherence to recommended care. If these programs are redesigned accordingly, individuals who had reported to have forgone a health service recommended by their treating physician due to cost-sharing, would be more likely to use this service. Such redesigned programs provide a policy option to reduce adverse health effects of cost-sharing in these groups. Considering the upcoming shift from volume-based to value-based health care provision, insights into the characteristics of a cost-sharing program that stimulates the use of recommended care may help to design value-based insurance plans.
- Open Access
- 1 June 2018
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 126, 92-99
Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review
- 1 June 2018
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 126, 92-99
Open AccessPrediction models for endometrial cancer for the general population or symptomatic women: A systematic review